The difference in one line
Retatrutide is an agonist at three receptors — GLP-1, GIP and glucagon. Tirzepatide is an agonist at two of those three, GLP-1 and GIP, and has no glucagon receptor activity. The glucagon receptor is the whole of the categorical difference between them.
Everything else worth saying is either a consequence of that or a caution about what the labels do not tell you. This page covers the pairwise comparison; the full account of tirzepatide is in what is tirzepatide.
Side by side
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1, GIP, glucagon | GLP-1, GIP |
| Label | Triple agonist | Dual agonist |
| Chain length | Single continuous chain | 39 amino acids |
| Persistence strategy | Fatty-acid modification | C20 fatty diacid, Aib substitution |
| UK status of the molecule | No marketing authorisation | Active ingredient of authorised medicines |
What adding a third receptor changes
GLP-1, GIP and glucagon are closely related members of one peptide family, with conserved segments in common. That shared ancestry is why a single engineered chain can be tolerated at more than one of their receptors at all — and it is why "triple agonist" describes receptor coverage rather than construction. Retatrutide is one continuous chain, not three linked fragments, and there is no portion of it that is the glucagon part.
The glucagon receptor is nonetheless a genuinely different addition rather than a third variation on a theme. GLP-1 and GIP are both incretins — released from the gut in response to nutrients — while glucagon is a pancreatic hormone with, broadly, opposing metabolic direction. A molecule engaging all three is engaging signals that are not simply additive, which is precisely what makes the class interesting to study and what makes predicting its net behaviour from the label impossible.
For in-vitro work the practical consequence is that retatrutide requires a three-receptor assay panel where tirzepatide requires two, and a study comparing them needs the glucagon receptor arm even though only one compound acts there — otherwise the difference between them is exactly the thing the experiment cannot see.
What the labels do not tell you
This is the part most comparisons get wrong. "Triple" versus "dual" counts receptors. It says nothing about potency at any of them.
A triple agonist can be less potent at a shared receptor than a dual agonist is. Relative potency at each receptor is a property of the specific sequence, established by assay, and it is not implied by the category — so "triple beats dual" is not a claim the labels support in any respect. Comparing two molecules in this class means comparing their potency figures receptor by receptor, and those figures come from experiments run under stated conditions, not from the name of the category.
Nor does receptor coverage imply anything about signalling bias, receptor internalisation rate, or stability, all of which differ between molecules and all of which bear on what an experiment observes.
The regulatory positions are not comparable
The two compounds sit in materially different places, and this is the one difference between them that has nothing to do with pharmacology.
Retatrutide holds no UK marketing authorisation, and the MHRA products register carries no entry for it — something any reader can confirm directly. Tirzepatide, by contrast, is the active ingredient of authorised medicines in the UK and elsewhere.
That difference matters less than it appears for present purposes, because a marketing authorisation attaches to a specific finished product from a specific manufacturer, not to a molecule. Research-grade tirzepatide is not an authorised medicine, is not manufactured or released under a medicines framework, and carries none of the documentation authorisation implies. See are peptides legal in the UK.
Common questions
What is the difference between retatrutide and tirzepatide?
The glucagon receptor. Retatrutide is an agonist at GLP-1, GIP and glucagon receptors; tirzepatide covers GLP-1 and GIP only. That is a difference in which receptors are activated, and it is the whole of the categorical difference between them.
Is a triple agonist stronger than a dual agonist?
The labels do not support that claim. They count receptors and say nothing about potency at any of them — a triple agonist can be less potent at a shared receptor than a dual agonist. Relative potency is a property of the specific sequence, established by assay.
Why can one peptide chain activate three different receptors?
Because GLP-1, GIP and glucagon are closely related members of one peptide family with conserved segments in common, so a single engineered sequence can be tolerated at all three receptors. "Triple agonist" describes coverage, not construction — retatrutide is one continuous chain, not three linked fragments.
Which of the two is authorised as a medicine in the UK?
Tirzepatide is the active ingredient of authorised medicines; retatrutide holds no UK marketing authorisation. But an authorisation attaches to a specific finished product, not to the molecule, so research-grade tirzepatide is not an authorised medicine either.
Continue reading
Research use only
Every compound named on this page is supplied by Peptide Global strictly for laboratory research use only. Nothing here is for human or veterinary use. These are not foods, supplements or cosmetics, and they are not intended to diagnose, treat, cure or prevent any disease. Nothing on this page is medical, veterinary or legal advice, and no part of it describes administration to a person or an animal.
Purchasers are responsible for their own compliance with applicable law and with the requirements of their institution or ethics committee. At checkout, purchasers confirm they are a qualified researcher aged 18 or over and that they accept the Research-Use-Only Policy and Terms & Conditions.
